LSTM Home > LSTM Research > LSTM Online Archive

How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance.

Hastings, Ian ORCID: https://orcid.org/0000-0002-1332-742X (2011) 'How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance.'. Trends in parasitology, Vol 27, Issue 2, pp. 67-72.

Full text not available from this repository.

Abstract

Antimalarial drug therapies containing artemisinins, 'ACTs', have become the mainstay for treating uncomplicated malaria in endemic countries. This is a major public health achievement requiring substantial political, financial and scientific input. The most compelling scientific argument for ACT deployment employed a very simple basic rationale that emphasised their role in slowing the origin of drug resistance while largely neglecting the additional role(s) of ACTs in slowing or preventing the spread of resistance once it has arisen. Recent reports suggest that early stages of resistance to artemisinins and/or its partner drugs could be occurring, thus it is timely to briefly review exactly how ACTs slow the origin and spread of resistance and to interpret the threat of resistance within this context.

Item Type: Article
Subjects: QV Pharmacology > Anti-Inflammatory Agents. Anti-Infective Agents. Antineoplastic Agents > QV 256 Antimalarials
QW Microbiology and Immunology > QW 45 Microbial drug resistance. General or not elsewhere classified.
WC Communicable Diseases > Tropical and Parasitic Diseases > WC 770 Therapy
Faculty: Department: Groups (2002 - 2012) > Molecular & Biochemical Parasitology Group
Digital Object Identifer (DOI): https://doi.org/10.1016/j.pt.2010.09.005
Depositing User: Mary Creegan
Date Deposited: 16 Jun 2011 11:51
Last Modified: 19 Sep 2019 11:29
URI: https://archive.lstmed.ac.uk/id/eprint/2035

Statistics

View details

Actions (login required)

Edit Item Edit Item